The Multiple Sclerosis Trust reacted angrily yesterday to news that the Medical Regulatory Healthcare Agency, the UK’s drug watchdog, is demanding more tests on a treatment for the condition derived from cannabis.
Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada.
GW Pharma forced to hold back on cannabis treatment in UK
The Multiple Sclerosis Trust reacted angrily yesterday to news that the Medical Regulatory Healthcare Agency, the UK’s drug watchdog, is demanding more tests on a treatment for the condition derived from cannabis.
Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada.